Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sinohealth Holdings Limited
中康控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 2361)

VOLUNTARY ANNOUNCEMENT
SINOHEALTH HOLDINGS'S STRATEGIC UPGRADE

This announcement is made by Sinohealth Holdings Limited (the "Company", or together with its subsidiaries, the "Group") on a voluntary basis to update the shareholders of the Company and potential investors on the latest business development of the Group.

I. Strategic Positioning

The board of directors of the Company is pleased to announce that, as at the date of this announcement, the Company's strategy is formally being upgraded from being a "provider of digital and intelligent solutions focused on the life sciences sector" to advancing towards becoming a "comprehensive AI technology services company based on the data assets and ecological resources of the health industry".

II. Core Competencies

The Company's strategic upgrade from "Digital Technology Services" to "AI Decision-making and Intelligent Services" is founded upon its integrated capabilities currently being built around "data + models + scenarios + ecosystem":

1. Dual-Domain Large Models from "Cognition to Decision"

   (1) "Woodpecker" (Medical Large Model): Built on medical literature, patient records and pharmacological knowledge graphs, and evaluated with feedback from medical experts, it is capable of professionally and accurately understanding complex medical terminology and compliance requirements.

   (2) "Tiangong No.1" (Decision-making Large Model): By deeply integrating years of accumulated diversified market data and industry logic with medical knowledge, it can translate medical knowledge into actionable strategies, resource allocation plans and professional sales execution, dedicated to achieving a value closed loop from "medical cognition" to "commercial outcomes."

2. A Multi-dimensional Data Moat and Industrial Smart Platform

The Company possesses a diverse pool of health industry data resources, spanning a wide range of medical institutions, physical examination centres and retail pharmacies. This enables us to build a comprehensive, multi-dimensional data system that integrates in-hospital and out-of-hospital services, online and offline channels, as well as prevention and treatment. At the same time, leveraging 18 years of accumulated industry know-how, we decipher the business logic of data, break down complex operational scenarios and facilitate key decision-making.

3. A Comprehensive AI Service System and Our Teamwork Ability

The Company has established an AI service system from a foundational platform to front-end applications. Supported by a multi-dimensional service model, the system empowers us with capabilities to satisfy different requirements of clients ranging from small and medium-sized enterprises to group customers. Our team and partners command cutting-edge AI expertise and in-depth pharmaceutical experience. Medical technologies and scenarios will be further deeply integrated to ensure the successful implementation of our products and deliver quantifiable value.

III. Business Planning and Implementation Scenarios

Guided by the latest strategy of the Company, Sinohealth will fully leverage its core capabilities to establish AI implementation across four key scenarios in the healthcare industry, namely marketing, healthcare, pharmacy, and health management, thereby driving the transformation and upgrading of the sector.

On the marketing front, we have launched commercial AI agents and leveraged the "Tiangong No.1" decision-making model to achieve more efficient generation and implementation of marketing strategies, empowering pharmaceutical companies to reduce costs and increase efficiency. In the medical field, supported by the Company's self-developed "Woodpecker" medical model, we will focus on developing the "iMDT" intelligent agent for multi-disciplinary joint consultations on severe illnesses, enhancing the quality of MDT decision-making and providing more precise empowerment for doctors and hospitals. For the pharmacy sector, improving professional service capabilities is critical to driving performance growth. Therefore, we will pursue breakthroughs and implementation across five key dimensions including operational insights, products, diseases, membership services and staff support, helping pharmacies achieve intelligent closed-loop management from product selection to membership services. In health management, the Company is committed to building a comprehensive "prevention-screening-intervention" health management system. By developing a multi-dimensional intelligent agent matrix, we will provide more precise services in areas such as health management, patient medication guidance, and rehabilitation support.

IV. Outlook

Moving forward, the Company will adhere to its established development strategy, leveraging industrial-scale data to build an efficient collaborative ecosystem of intelligent agents in the healthcare industry, and continue to lead the industry into a new era of intelligent transformation.

The Company hereby informs its shareholders and potential investors of its latest business developments. The information contained in this announcement is based on the Company's preliminary assessment and currently available information, and has not been audited, reviewed, or approved by the auditor of the Company. The figures set out herein are for reference purposes only and do not constitute any forward-looking statements or profit forecasts of the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinohealth Holdings Limited
Wu Yushu
Chairman

Hong Kong, 15 January 2026

As at the date of this announcement, the executive Directors are Mr. Wu Yushu and Ms. Wang Lifang, the non-executive Director is Mr. Fu Haitao, and the independent non-executive Directors are Ms. Wang Danzhou, Ms. Chui Hoi Yam and Mr. Wei Bin.